GlassScriptPhysician profile
Frank J Fera
NPI 1588750186
$8,654.58
in general payments reported to CMS, 2019-2025
41 companies · $20.00 in 2025
The $20.00 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,709 · 2020: $948 · 2021: $1,648 · 2022: $1,465 · 2023: $1,661 · 2024: $1,203 · 2025: $20.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,884.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,414.52 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,251.44 | 2019-2024 | |
| Glaxosmithkline, LLC. | $845.62 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.55 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $453.65 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $415.41 | 2019-2024 | |
| Amgen INC. | $398.09 | 2019-2024 | Otezla, Repatha, Evenity |
| Janssen Pharmaceuticals, INC | $376.53 | 2019-2022 | |
| Abbott Laboratories | $260.21 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2, Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $242.34 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.01 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $152.97 | 2019-2022 | |
| Allergan, INC. | $146.58 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $144.33 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $142.33 | 2019-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $138.74 | 2019-2022 | |
| Mannkind Corporation | $132.11 | 2019-2022 | |
| Exact Sciences Corporation | $106.22 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $103.80 | 2022 | |
| Renalytix Ai, INC. | $99.97 | 2022-2023 | Kidneyintelx Blood Collection Convenience Kit |
| Eisai INC. | $97.76 | 2020-2021 | |
| Sanofi Pasteur INC. | $80.47 | 2019-2023 | |
| Seqirus USA INC | $67.34 | 2020-2024 | Fluad, Flucelvax, Fluad Quadrivalent |
| Kowa Pharmaceuticals America, INC. | $65.76 | 2019-2023 | Seglentis |
| Tactile Systems Technology INC | $62.47 | 2024 | Flexitouch Plus, Entre Plus |
| Astellas Pharma US INC | $61.33 | 2020-2021 | |
| Amarin Pharma, INC. | $60.64 | 2019-2021 | |
| Daiichi Sankyo INC. | $54.56 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $52.01 | 2019-2023 | Eliquis |
| Esperion Therapeutics, INC. | $50.95 | 2021 | |
| Lundbeck LLC | $40.42 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $36.79 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $33.97 | 2021 | |
| Organogenesis INC. | $24.17 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $23.32 | 2019-2020 | |
| Ibsa Pharma INC. | $18.24 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.42 | 2024 | Farxiga |
| Horizon Therapeutics Plc | $14.06 | 2021 | |
| Dexcom, INC. | $13.83 | 2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $13.67 | 2023 | |
| Amneal Pharmaceuticals LLC | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Fera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.